Published in Genome Biol on June 25, 2002
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
In support of descriptive studies; relevance to translational research. J Transl Med (2007) 1.82
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res (2009) 1.71
RNA amplification for successful gene profiling analysis. J Transl Med (2005) 1.55
Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med (2010) 1.39
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol (2007) 1.38
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Genome wide transcriptional analysis of resting and IL2 activated human natural killer cells: gene expression signatures indicative of novel molecular signaling pathways. BMC Genomics (2007) 1.30
Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling. J Transl Med (2003) 1.28
Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med (2004) 1.27
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest (2005) 1.24
Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med (2006) 1.21
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer (2011) 1.19
Memory T cells have gene expression patterns intermediate between naive and effector. Proc Natl Acad Sci U S A (2005) 1.18
Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Med Genomics (2011) 1.17
Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines (2010) 1.15
Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res (2011) 1.10
Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther (2014) 1.06
DNA array analysis of interleukin-2-regulated immediate/early genes. Med Immunol (2002) 1.06
The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother (2009) 1.06
CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer (2013) 1.06
Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease. Clin Exp Immunol (2009) 1.03
Melanoma-restricted genes. J Transl Med (2004) 1.03
T-cell clonotypes in cancer. J Transl Med (2004) 0.91
Changing paradigm through a genome-based approach to clinical and basic immunology. J Transl Med (2004) 0.86
GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells. J Transl Med (2008) 0.86
Understanding the response to immunotherapy in humans. Springer Semin Immunopathol (2005) 0.83
Advances in immunotherapy for melanoma. BMC Med (2016) 0.83
Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther (2011) 0.82
New take on comparative immunology: relevance to immunotherapy. Immunotherapy (2009) 0.82
Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy. J Transl Med (2004) 0.80
Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact. Br J Cancer (2009) 0.79
A compendium of monocyte transcriptome datasets to foster biomedical knowledge discovery. F1000Res (2016) 0.78
Role of interleukin-32 in chronic rhinosinusitis. Curr Opin Allergy Clin Immunol (2013) 0.78
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology (2017) 0.77
A curated compendium of monocyte transcriptome datasets of relevance to human monocyte immunobiology research. F1000Res (2016) 0.77
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. Cancer Immunol Res (2016) 0.76
Update on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther (2015) 0.76
Reflections upon human cancer immune responsiveness to T cell-based therapy. Cancer Immunol Immunother (2012) 0.76
Turning laboratory findings into therapy: a marathon goal that has to be reached. Pol Arch Med Wewn (2009) 0.75
PGC-1α-Dependent Mitochondrial Adaptation Is Necessary to Sustain IL-2-Induced Activities in Human NK Cells. Mediators Inflamm (2016) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Exploring the new world of the genome with DNA microarrays. Nat Genet (1999) 19.05
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
High-fidelity mRNA amplification for gene profiling. Nat Biotechnol (2000) 6.97
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity (2001) 3.45
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol (2001) 2.98
IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A (2000) 2.80
Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer (1998) 1.69
Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer (1986) 1.60
Genomic views of the immune system*. Annu Rev Immunol (2000) 1.60
Probing lymphocyte biology by genomic-scale gene expression analysis. J Clin Immunol (1998) 1.46
Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J Exp Med (1989) 1.35
Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol (1988) 1.30
An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am (1997) 1.20
Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol (1989) 1.13
Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am (2000) 1.11
Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer (1994) 1.11
Granulysin expression is a marker for acute rejection and steroid resistance in human renal transplantation. Hum Immunol (2001) 1.04
Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol (2000) 1.02
Interleukin-2 in the treatment of renal cancer. Semin Oncol (2000) 0.98
Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res (1986) 0.94
Short-term kinetics of tumor antigen expression in response to vaccination. J Immunol (2001) 0.91
Genomic analysis of renal allograft dysfunction using cDNA microarrays. Transplant Proc (2001) 0.81
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood (2004) 5.86
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Transfusion of older stored blood and risk of death: a meta-analysis. Transfusion (2011) 3.94
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res (2007) 2.69
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest (2004) 2.66
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 2.24
Mortality increases after massive exchange transfusion with older stored blood in canines with experimental pneumonia. Blood (2012) 2.22
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10
Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med (2003) 1.88
Randomization in clinical trials of titrated therapies: unintended consequences of using fixed treatment protocols. Crit Care Med (2007) 1.88
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
What's next in translational medicine? Clin Sci (Lond) (2007) 1.85
In support of descriptive studies; relevance to translational research. J Transl Med (2007) 1.82
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock (2013) 1.74
Global transcriptome analysis of human bone marrow stromal cells (BMSC) reveals proliferative, mobile and interactive cells that produce abundant extracellular matrix proteins, some of which may affect BMSC potency. Cytotherapy (2011) 1.73
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
The dual role of IL-10. Trends Immunol (2003) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol (2006) 1.69
The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res (2006) 1.68
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
Washing older blood units before transfusion reduces plasma iron and improves outcomes in experimental canine pneumonia. Blood (2013) 1.66
The immunologic constant of rejection. Trends Immunol (2008) 1.62
Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res (2012) 1.61
Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology (2012) 1.61
Cytokines and Immune Response in the Tumor Microenvironment. J Immunother (1991) (2001) 1.59
Obstacles and opportunities in translational research. Nat Med (2005) 1.59
Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med (2008) 1.57
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLoS Genet (2008) 1.57
Common cancer biomarkers. Cancer Res (2006) 1.56
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 1.56
The hazards of blood transfusion in historical perspective. Blood (2008) 1.54
What have we learned from cancer immunotherapy in the last 3 years? J Transl Med (2014) 1.52
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol (2011) 1.51
An immunologic portrait of cancer. J Transl Med (2011) 1.50
Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol (2002) 1.48
Research translation: a new frontier for clinical laboratories. Clin Chem Lab Med (2006) 1.48
Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics (2004) 1.45
Hemochromatosis subjects as allogeneic blood donors: a prospective study. Transfusion (2003) 1.45
Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor. Int J Cancer (2007) 1.43
Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res (2005) 1.39
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol (2007) 1.38
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res (2009) 1.38
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res (2008) 1.38
Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res (2010) 1.37